We’re delighted to announce the appointment of Deborah Keller as the new chair of our Board. Deborah’s appointment signals the next phase in our robust growth strategy designed to continuously build our team of the best-of-the-best clinical and commercial experts, delivering cutting-edge end-to-end solutions for our clients across the product lifecycle.
With more than 3 decades of experience, she brings exceptional leadership from a career supporting and scaling fast-growing, people-based businesses in healthcare, including her role as the CEO of Covance where she led a team of over 13,000 employees in 60 countries and was responsible for more than $2.6 billion in business.
Deborah has dedicated her life to improving patient outcomes and uncovering innovative ways to bring value to the pharmaceutical industry. She will bring unique knowledge and innovative thinking that will empower stakeholders to shape and affect connections between people and life-enhancing therapies. Her counsel will also be invaluable for leading Fishawack Health to consolidate its integration, scale its client value proposition and global infrastructure.
Deborah Keller, Fishawack Health Chair
Deborah adds, “The team’s exceptional expertise stood out to me. As someone who worked at the same company over a long period and eventually led the leadership team, I know how important it is to allow every employee to develop, grow and thrive. Doing so will ensure we better deliver for our clients, patients, and healthcare professionals.”
Deborah’s appointment follows the recent acquisitions of The Hive Health Group and StoneArch. We are now powered by a 950+ and growing, globe-spanning pack of strategic, creative, and scientific experts, operating across 17 offices in 13 cities in the US and UK, with combined revenue of more than $150 million.
Read the full press release on PharmaLive.